A Novel Drug for Migraine
THE OPPORTUNITY
The market opportunity in migraine is immense
The Problem
Migraine is one of the world's most debilitating diseases.
More than one billion affected worldwide
The Gap
It is also one of the most poorly managed conditions.
60-80% fail on 1st & 2nd-line treatments
The Market
The addressable market for treating migraine is $31BN*
* Research by LifeSci Consulting
THE SCIENCE
Cannabinoids are one of the most exciting novel mechanisms in migraine science.
Cannabinoids engage multiple targets in and outside of the endocannabinoid system (ECS) to treat complex diseases like migraine via various validated pathways.
A combination of CBD:THC showed the greatest efficacy for migraine in an independent clinical trial at UC San Diego.
Cannabinoid drug development has major momentum globally, and was prioritized by a 2025 White House Executive Order.
Our Story
We are building first-in-class and best-in-class cannabinoid combinations for migraine.
Institutional Backing
$3.4M in NIH grants to advance into clinical trials
Momentum
Phase 1 clinical trial ongoing, phase 2 to start in 2026
Issued Patents
USPTO issued CoM patents and layered IP strategy
Our RESEARCH PARTNERS
OUR TEAM
We are world-class leaders in cannabinoid and migraine drug development.
Founder & CEO
George Pappas
25-year pioneer in cannabinoid R&D, regulations, and markets at world leading organizations
Chief Medical Officer
Detlef Albrecht MD
5 US & 5 EU market authorizations including in migraine and pain. Raised over $400M for drug development
Clinical Lead
Alan Rapoport MD
Past President, International Headache Society; involved in >100 migraine clinical trials
Scientific Lead
Greg Dussor PhD
A renowned migraine and pain preclinical researcher and serial entrepreneur
Nonclinical / Clinical Safety Lead
Ryan Lanier PhD
An expert in cannabinoid clincial trial design and abuse potential
Regulatory Affairs Lead
Terry Ocheltree PhD RPh
Former FDA Division Director & CMC SME who led the Agency's botanical drug guidance
Clinical Operations Lead
Sarah Thayer
20 yrs VP level, building and leading Clinical Ops teams in large / small entities
Nonclinical / Clinical Pharmacology
Zou Zhou PhD
Leader in physiologically based PK/PD modeling cannabinoid combinations
Program Management Lead
Joe Seroogy
20 yrs VP level project, pipeline, and CMC management in all development stages
OUR ADVISORS
And we are supported by world-class advisors and partners
Stephen Wright MD
Former Chief Medical Officer
GW Pharmaceuticals
Messoud Ashina MD PhD
Former President
Intl. Headache Society
Steve Kuemmerle PhD
Former Venture Head
Abbot
Gary Winer
Former CEO
Abbvie Japan
Rob Schickel PhD
Founder
Nuago Therapeutics
Ryan Humphries
Board Member
Delphian Therapeutics
Rafael Escandon DrPH, PhD, MPH
Fmr. VP Clinical Ops, Labrys
AJOVY
Mike Rainey
Former Life Science Head
Accenture
OUR Blog
Latest Updates
Delphian Therapeutics' Cannabinoid Migraine Research Named Editor's Choice in the Journal of the International Headache Society
Delphian Therapeutics Awarded $2.9M Phase 2 SBIR Grant from NIH to Advance Cannabinoid Migraine Drug to First-in-Human Clinical Trials
Delphian Therapeutics Closes $2.7M Seed Round to Advance S1-221 Cannabinoid Migraine Therapeutic into Phase 1 Clinical Trials